\u2003In this study-level meta-analysis, we evaluated the clinical outcome with nonvitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with cancer
Background: Direct oral anticoagulants (DOACs) are recommended as first-line anticoagulants in patie...
Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The stud...
The global real-life impact of non-vitamin K antagonist oral anticoagulants (NOACs) introduction in ...
In this study-level meta-analysis, we evaluated the clinical outcome with nonvitamin K antagonist o...
Atrial fibrillation (AF) is commonly diagnosed in the setting of active cancer. Because of an increa...
Background and aim. Cancer and atrial fibrillation (AF) may be associated, and anticoagulation, eith...
The aim of the present meta-analysis was to evaluate the efficacy and safety of non-vitamin-K oral a...
International audienceAbstract Objective Existing evidence on the association between vitamin K anta...
Use of the non-vitamin K antagonist oral anticoagulants (NOACs) is endorsed by current guidelines fo...
This study investigated the efficacy and safety of novel oral anticoagulants (NOACs) in patients wit...
This study sought to investigate the relative efficacy and safety of non-vitamin K oral anticoagulan...
BACKGROUND AND OBJECTIVES: There are limited data on the use of non-vitamin K antagonist oral antico...
This observational study aimed to investigate the efficacy and safety of non-vitamin K antagonist or...
Background-Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagon...
BACKGROUND:This study sought to investigate the relative efficacy and safety of non-vitamin K oral a...
Background: Direct oral anticoagulants (DOACs) are recommended as first-line anticoagulants in patie...
Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The stud...
The global real-life impact of non-vitamin K antagonist oral anticoagulants (NOACs) introduction in ...
In this study-level meta-analysis, we evaluated the clinical outcome with nonvitamin K antagonist o...
Atrial fibrillation (AF) is commonly diagnosed in the setting of active cancer. Because of an increa...
Background and aim. Cancer and atrial fibrillation (AF) may be associated, and anticoagulation, eith...
The aim of the present meta-analysis was to evaluate the efficacy and safety of non-vitamin-K oral a...
International audienceAbstract Objective Existing evidence on the association between vitamin K anta...
Use of the non-vitamin K antagonist oral anticoagulants (NOACs) is endorsed by current guidelines fo...
This study investigated the efficacy and safety of novel oral anticoagulants (NOACs) in patients wit...
This study sought to investigate the relative efficacy and safety of non-vitamin K oral anticoagulan...
BACKGROUND AND OBJECTIVES: There are limited data on the use of non-vitamin K antagonist oral antico...
This observational study aimed to investigate the efficacy and safety of non-vitamin K antagonist or...
Background-Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagon...
BACKGROUND:This study sought to investigate the relative efficacy and safety of non-vitamin K oral a...
Background: Direct oral anticoagulants (DOACs) are recommended as first-line anticoagulants in patie...
Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The stud...
The global real-life impact of non-vitamin K antagonist oral anticoagulants (NOACs) introduction in ...
DOI
Add to ORKG